Washington State University researchers provided computer analyses for a new gene therapy study published in Science Translational Medicine.
The study – conducted by the Fred Hutchinson Cancer Research Center in Seattle and published May 9 – found stem cell gene therapy could protect blood cells from damage by chemotherapy in patients suffering from glioblastoma (malignant brain tumors), thereby extending life expectancy.
The WSU laboratory of co-author Grant D. Trobridge, assistant professor of pharmaceutical sciences, developed bioinformatics software that aided the Fred Hutchinson researchers in evaluating the safety of the procedure. The approach was to remove blood stem cells, add a gene
Dean Third used to look forward to weekends spent refereeing local football matches, and outings with his young family. But now even walking to the end of the road can leave him breathless and exhausted.
For the past four years, the father of four has suffered from dilated cardiomyopathy (DCM), a disease of the heart muscle which causes it to enlarge, affecting its ability to pump blood to the arteries.
The condition afflicts 12,000 people in the UK, and for most sufferers the cause is unknown. If uncontrolled it can be fatal, and patients must adhere strictly to a regime of
A group of British doctors are preparing for human clinical trials that will take a person’s bone marrow stem cells, transform them into heart stem cells and inject them into the heart, where they can go to work repairing damage.
“Placing heart stem cells into the heart to repair has a very good chance of working; because the stem cells are the patient’s own there are no problems with rejection,” said Professor Sian Harding, of Imperial College London.
The British researchers plan to use a technique that was pioneered at the Mayo Clinic. They will remove 40 milliliters of bone marrow
Image via Wikipedia
Complications and unanticipated side-effects that have slowed the progression of stem cell studies from the lab to the clinic could soon change, researchers say.
For a decade, stem cells have tantalized scientists and patients with their promise to regenerate damaged tissues and offer treatments for incurable diseases.
No one hears, however, about the individuals who died due to complications of surgery, said Dr. Hans Keirstead, a Canadian researcher who made a paralyzed rat walk back in 2004 by injecting its spinal cord with cells derived from human embryonic stem cells.
Keirstead’s lab at the University of California-Irvine just received approval
The accumulation of irreparable cellular damage restricts healthspan after acute stress or natural aging.
Senescent cells are thought to impair tissue function, and their genetic clearance can delay features of aging.
Identifying how senescent cells avoid apoptosis allows for the prospective design of anti-senescence compounds to address whether homeostasis can also be restored.
Here, we identify FOXO4 as a pivot in senescent cell viability. We designed a FOXO4 peptide that perturbs the FOXO4 interaction with p53.
In senescent cells, this selectively causes p53 nuclear exclusion and cell-intrinsic apoptosis.
Under conditions where it was well tolerated in vivo, this FOXO4 peptide neutralized doxorubicin-induced chemotoxicity.